Cargando…
Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
The use of antibody-drug conjugates (ADCs) is expanding in several malignancies, including urothelial carcinoma where two of these medications have been approved for use and several others remain under study. ADCs act by binding to specific cell surface proteins, delivering anticancer agents directl...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846350/ https://www.ncbi.nlm.nih.gov/pubmed/36686762 http://dx.doi.org/10.3389/fonc.2022.1069356 |